Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Response to Election/Restriction filed on September 9, 2026 is acknowledged. Claims 1-6, 8-10, 12, 14, 17-19, 24, 27-28, 30, 33, 35 are pending in the instant application.
Election/Restrictions
Applicant elected without traverse Group I (claims 1-6, 8, 17-19, 24) and without traverse SEQ ID NO:24 as the fusion protein and IIoprost as the lipid from Lists I-II in the reply filed September 9, 2026.
The restriction is deemed proper and is made FINAL in this office action. Claims 9-10, 12, 14, 27-28, 30, 33, 35 are withdrawn from consideration as being drawn to a non-elected invention.
Claims 1-6, 8, 17-19, 24 are examined on the merits of this office action.
Claim Rejections - 35 USC § 112, First Paragraph
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-6, 8, 17-19, 24 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention.
MPEP § 2163 states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus.
Scope of the claims
Claim 1 broadly recites a fusion protein comprising ApoA1 and ApoM without specifying particular amino acid sequences, sequence identity thresholds, fusion orientations or biological activities. Claims 2, 3 end 8 further define the proteins by reference to specified sequences and at least 90 percent sequence identity, while claims 4 through 6 address fusion orientation and linker arrangements. Claims 17-19 and 24 extend the subject matter to lipid containing compositions and nanoparticles. In the specification, paragraphs 0026-0029 describe ApoA1 and ApoM sequences having as little as 70% amino acid sequence identity to specified native human and murine sequences, including embodiments with or without signal sequences. At 70% sequence identity, approximately 30% of the line amino acid positions may differ from the reference sequence. Such variations may affect protein folding, lipid association, ligand binding and biological activity. Thus, the claims potentially encompass a broad genus of structurally diverse fusion proteins. The relevant written description inquiries whether the specification reasonably conveys possession of the breath rather than merely the particular fusion protein experimentally demonstrated.
Therefore, to meet the written description requirement of 35 U.S.C. § 112, first paragraph, the specification must disclose a representative number of species that meet both the structural and functional limitations of the genus or the specification and/or the prior art must identify the structural elements that correlate to the claimed function in a manner that demonstrates to one of ordinary skill in the art that Applicant was in possession of the claimed genus at the time the application was filed.
Actual Reduction to Practice
MPEP § 2163 states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice. A “representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus.
The disclosure primarily describes murine ApoA1-ApoM fusion protein comprising native murine ApoA1 amino acids 1-264, gly ser linker, and murine ApoM amino acids 21-190, together with six histidine tag. The ApoA1 portion retains its native signal sequence, whereas the ApoM portion lacks its end terminal signal sequence. The example demonstrates expression, purification, lipid association, in biological activity of this construct, including S1P related receptor signaling, endothelial barrier protection, and anti-inflammatory effects.
However, the examples do not appear to demonstrate fusion proteins incorporating ApoA1 or ApoM variants modified to exhibit 70-90% sequence identity to the native reference sequences. Although actual reduction to practice of every claimed species is not required, the experimental disclosure appears limited principally to one native sequence based murine fusion construct. Thus, the examples provide support for the particular embodiment but may not establish possession of the broader genus encompassed by the claims.
Sufficient relevant identifying characteristic
MPEP § 2163 states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination thereof.
The specification identifies particular ApoA1 and ApoM sequences through SEQ ID Nos:1-6, 27-28, and fusion protein sequences through SEQ ID Nos:23-24. It also describes domain arrangements, signal sequences, and possible linkers. These disclosures provide relevant structural characteristics for the specifically identified proteins infusion constructs. However the specification does not appear to identify which amino acid residues must remain conserved, which substitutions are permissible, or which structural features distinguish functional ApoA1 and ApoM variants across the broadly disclosed sequence identity ranges. In particular, the disclosure does not appear to establish common structural characteristics sufficient to identify substantially diverging variants that retain the relevant properties of both protein components when combined in a fusion protein. Although the native reference sequences provide structural guidance, disclosure of particular sequences and percentage identity ranges does not necessarily demonstrate possession of every variant within those ranges. Therefore, specification lacks sufficient identifying characteristics to support the full scope of the claims.
Physical/Chemical Properties
The specification describes ApoA1 as a lipid associated protein capable of forming HDL-like particles and ApoM as a lipocalin protein capable of binding lipid mediators (in particular, sphingosine 1 phosphate). Experimentally produced fusion protein is characterized through expression, purification, electrophoretic analysis, chromatographic behavior, information of lipid associated compositions. However, amino acid substitutions may alter protein folding, hydrophobicity, stability, solubility, lipid association and ligand binding. The alterations in ApoA1 sequence could affect lipid interactions whereas changes in ApoM could affect structural integrity of its lipid binding. The specification does not appear to demonstrate that fusion proteins containing substantially varying ApoA1 and ApoM sequences would retain comparable physical and chemical properties. The specification does not identify defining physiochemical characteristics applicable throughout the claim genus.
Functional characteristics when coupled with a known or disclosed correlation between function and structure:
The specification Identifies several desired functions of the fusion protein, including phospholipid association, lipid mediator binding and transport, S1P receptor activation, endothelial barrier protection, an anti-inflammatory activities. These functions arise from the complementary biological roles of ApoA1 and ApoM, ApoA1 providing A lipid associated structural scaffold, while ApoM vines and chaperones biologically active lipid mediators including S1P. Although these functions are known for native ApoA1 and ApoM, the specification does not appear to establish a sufficiently detailed correlation between amino acids sequence variation and preserving this functions throughout the genus. For ApoA1, the specification does not identify permissible substitutions within the lipid interacting regions that preserve association. For ApoM, it does not appear to identify which substitutions within the ligand binding pocket preserves S1P binding and chaperon activity. The experimental results primarily establish the functional properties of the particular murine fusion construct rather than a representative range of sequence variants within the fusion protein. Claim 18 presents an additional concern because it expressly addresses receptor agonist or antagonist activity. The specification does not appear to demonstrate representative fusion protein compositions exhibiting the full range of claimed receptor activities and or antagonist activities,
Method of Making
The specification describes recombinant production of the ApoA1-ApoM fusion protein, including nucleic acid construction expression in cells, purification using a histidine tag and preparation of lipid associated compositions containing S1P or iloprost. However, the ability to construct and express variants does not necessarily demonstrate possession of the claimed genus. The specification does not appear to provide a method for identifying which sequence substitutions preserve the structural and functional characteristics of both protein domains when incorporated into a fusion protein.
Conclusion
The specification appears to provide written description support for the exemplified murine ApoA1-ApoM fusion protein but not for the full breadth of the claim genus. Although the disclosure encompasses substantial sequence variation, it does not appear to provide representative variants, sufficient common structural characteristics, or an established structure function correlation demonstrating possession of the broader genus.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-6, 8, 17-19, 24 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-82 of copending Application No. 19615340 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because:
The instant application claims a fusion protein comprising ApoM and ApoA1 (see claim 1). The instant application further claims The fusion protein of claim 1, wherein ApoAl comprises an amino acid sequence that is 90% identical to any one of SEQ ID NOs: 1-2 or 27 (claim 2); The fusion protein of claim 1 or claim 2, wherein ApoM comprises an amino acid sequence that is 90% identical to any one of SEQ ID NOs: 3-4 or 28 (claim 3); N or C terminus attachment of ApoA1 to ApoM (see claims 4-5); a linker (claim 6); a lipoprotein comprising said fusion (claim 17) and a lipid such as S1P (claim 19); and a nanoparticle (claim 24)..
Copending Application claims A fusion protein comprising ApoAl and ApoM, wherein ApoAl comprises an amino acid sequence that is 90% identical to any one of SEQ ID NOs: 1, 3, or 5 and wherein ApoM comprises an amino acid sequence that is 90% identical to any one of SEQ ID NOs: 2 or 4” (which sequences overlap with the instantly claimed sequences). Copending Application further claims ApoA1 fused to the N-terminus or C-terminus of ApoM (see clams 4-5); a linker (claim 6); a lipoprotein comprising said fusion protein (see claim 30); wherein the lipid is S1P (see claim 32); and a nanoparticle (claim 42).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Closest prior Art
The closest prior art is park (2013), Bader (WO2012028526) and Lek (2016), which disclose various engineered apolipoprotein constructs and lipid-associated compositions. Park discloses a hybrid protein comprising the signal peptide of ApoA1 fused to ApoM lacking its native signal peptide, but does not teach fusion of the mature ApoA1 protein domain with ApoM. Bader teaches tetranectin ApoA1 fusion proteins, sequence variants, and lipid containing particles, but does not disclose ApoM as a fusion partner. Lek describes chimeric ApoA1/ApoE3 proteins that retain certain lipid binding and cholesterol transport function, but does not disclose ApoA1-ApoM fusion protein. Thus, although these references demonstrate that apolipoprotein fusion engineering and lipid associated compositions were known, none individually teach or disclose a fusion protein comprising both the mature ApoA1 and ApoM protein domains as presently claimed. Furthermore, the references do not establish that combining these particular protein domains would predictably retain their respective lipid association and lipid mediator chaperoning functions.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERINNE R DABKOWSKI whose telephone number is (571)272-1829. The examiner can normally be reached Monday-Friday 7:30-5:30 Est.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko Garyu can be reached at 571-270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ERINNE R DABKOWSKI/Primary Examiner, Art Unit 1654